Skip to main content

ICICI Lombard, EID Parry, and ICICI Prudential can give up to 12% return in the short term

On the technical front, now 13,000 should act as strong resistance for Nifty while 29,500 would be an immediate hurdle for Bank Nifty.

ICICI Lombard General Insurance Company | LTP: Rs 1,317.55 | Target price: Rs 1,480 | Stop loss: Rs 1,230 | Upside: 12%

For the last three months, the stock has been consistently moving lower in a downward sloping channel with the formation of the lower high and lower bottom pattern.

However, this week, the stock has once again moved back above its key resistance levels of Rs 1,320 with a breakout above the falling trendline of the sloping channel.

The breakout can be seen with rising volumes and positive divergences on secondary oscillators.

The stock is holding well above its long-term moving averages on daily and weekly intervals.

EID Parry India | LTP: Rs 301 | Target price: Rs 337 | Stop loss: Rs 273 | Upside: 12%

For the last nearly seven weeks, the stock has been consolidating in a broader range of Rs 265-295 along with consistent buying around support levels.

On the daily and weekly charts, the stock is holding well above its short and long-term moving averages.



At the current juncture, the stock has formed an inverted head and shoulder pattern on the daily charts and managed to give a breakout above the neckline of the pattern formation.

ICICI Prudential Life Insurance Company | LTP: Rs 449.70 | Target price: Rs 494 | Stop loss: Rs 415 | Upside: 10%

After testing Rs 487 levels in August, the stock was seen continuously trading lower in a downward sloping channel with the formation of the lower high and lower bottom pattern.

However, it managed to take support at its 200-day exponential moving average on the weekly charts and bounced back after forming a double bottom pattern at Rs 400 levels on the daily charts.

This week, the stock has once again moved back above its key resistance level of Rs 440 with the breakout above the falling trendline of the sloping channel.

The positive divergence on secondary oscillators with a breakout suggests further upside in the prices.

Disclaimer:- Investments in securities market are subject to risk. Consult your financial advisor before taking any of above calls.

Comments

Post a Comment

Popular posts from this blog

Taking Stock | Profit-booking pulls Nifty below 14,450; Sensex drops 549 points

  All the sectoral indices ended in the red with IT and PSU bank indices falling 2 percent each. The market remained under pressure on January 15 on the back of profit-booking across sectors amid weak global cues. At close, the Sensex was down 549.49 points or 1.11% at 49,034.67, and Nifty was down 161.90 points or 1.11% at 14,433.70. "The market witnessed profit-booking and following global trends. Nifty continues to resist 14,600 and has taken a dip towards 14,360. If the market closes below 14,380 levels, we might see a correction till the levels of 14,180-14,200. Momentum indicators like RSI, MACD are indicating a small correction in the markets," said Ashis Biswas, Head of Research at CapitalVia Global Research. All the sectoral indices ended in the red with IT and PSU bank falling 2 percent each. Broader markets performed in line with the main indices with BSE Midcap and Smallcap indices falling 1 percent each. Tech Mahindra, GAIL, HCL Tech, Wipro and ONGC...
Post a Comment
Read more

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...
Post a Comment
Read more

Similar to 2020, D-Street is at record high ahead of Budget 2021; will history repeat itself?

  Experts are of the view that a repeat of 2020 or what happened in March might not be possible but some consolidation cannot be ruled out. Back in March when everyone wanted to write-off 2020 from their books, hope and liquidity supported markets and investor sentiment. Nobody thought that after touching a 3-year low in March 2020, benchmark indices would give double-digit returns by the end of the year. The S&P BSE Sensex and Nifty50 rallied by about 15 percent in 2020 and the big outperformance came from the small and midcap stocks. The rally is still continuing in 2021. The S&P BSE Sensex, which climbed Mount 49K, is up over 3 percent while the Nifty50 is up over 4 percent so far in January. Sensex scaling the 49,000-mark and Nifty50 touching 14,500 levels ahead of the Budget 2021 could make anyone cautious about the strength of the rally. Back in January 2020, both Sensex and Nifty touched fresh highs ahead of Budget, and then the market fell like a pack of cards. The ...
Post a Comment
Read more